With the idea that platinum compounds that bind with DNA differently than 
cisplatin may be better-able to overcome platinum resistance in ovarian tumor, 
the monofunctional platinum complex tris(imidazo(1,2-α)pyridine) 
chloroplatinum(II) chloride (coded as LH6) has been synthesized and investigated 
for its activity, alone and in combination with the phytochemicals curcumin and 
quercetin, against human ovarian A2780, A2780(cisR) and A2780(ZD0473R) cancer 
cell lines. LH6 is found to be more active than cisplatin against the resistant 
cell lines and its bolus combinations with curcumin and quercetin are found to 
produce more pronounced cell kill. Whereas platinum accumulation from cisplatin 
is found to increase almost linearly with time, that from LH6 reaches a maximum 
at 4 h and is somewhat lowered at 24 h. It is possible that the presence of 
bulky hydrophobic imidazo (1,2-α-pyridine) ligand in LH6 facilitates its rapid 
uptake through the cytoplasmic membrane. Lower platinum accumulation at 24 h 
than at 4 h for LH6 can be seen to imply that efflux processes may be more 
dominant as the period of incubation is increased. When platinum-DNA binding 
levels at 24 h are compared, cisplatin is found to be associated with the higher 
level in the parent A2780 cell line and LH6 in the resistant A2780(cisR) cell 
line, in line with greater activity of cisplatin in the parent cell line and 
that of LH6 in the resistant cell line. If the observed in vitro activity of LH6 
is confirmed in vivo, it can be seen to have the potential for development as 
novel platinum based anticancer drug.